Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia | Zendy

AI Assistant Blog Pricing

Open Access

Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia

Author(s) -

Kamron Lotfi

Publication year - 2021

Language(s) - English

Resource type - Dissertations/theses

DOI - 10.36837/chapman.000294

Subject(s) - blinatumomab , clofarabine , lymphoblastic leukemia , medicine , refractory (planetary science) , oncology , leukemia , cytarabine , biology , astrobiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Empowering knowledge with every search

About

About Careers Publisher Partners Contact Us

Learn

FAQs Blog Terms of Use Privacy Policy

Discover

Explore

Copyright Knowledge E © 2025. All Rights Reserved.